Topical Microbicides Under Development 51 Preclinical

Microbicides currently under pre-clinical development are Alkyl sulfates, tobacco-derived antibodies and fusion proteins (HIV, HSV, HPV), anti ICAM-1 antibodies, betacyclodextrin, the entry/fusion inhibitors C85FL, K5-N, and OS(H), cyanovirin-N, lime juice, mandelic acid condensation polymer (SAMMA), MC1220 (lead compound in the dihydroxy alkyl benzyl oxopyrmimidine series), the vaginal defense enhancer MucoCept HIV, Novaflux proprietary product, and porphyrins (Table 1).

Table 1. Microbicides in Pre-clinical Trials (modified from the Alliance for Mic-robicide Development's Microbicide Research and Development Database (MRDD))

Product

Developer

Infectious agents in vitro and/or animal model data

Porphyrins

Emory University

HIV-l, Herpes simplex,

Neisseria gonorrheae

Alkyl sulfates

Pennsylvania State

HIV-l, Herpes simplex,

University

human papillomavirus,

Chlamydia trachomatis,

Neisseria gonorrheae

Antibodies and fusion

Mapp Biopharmaceutical,

HIV-l, Herpes simplex

proteins

Inc.

Anti ICAM-1 antibody

Johns Hopkins University

HIV-l

Betacyclodextrin

Johns Hopkins University

HIV-l

C85FL

Cornell University, Weill

HIV-l

Medical College

Cyanovirin-N

Biosyn, Inc.

HIV-l

K5-N, OS(H)

San Raffaele Scientific

HIV-l

Institute

Lime juice

University of Melbourne

HIV-l

Mandelic acid

Mount Sinai Medical

HIV-l, Herpes simplex,

condensation

School

human papillomavirus,

polymer (SAMMA)

Chlamydia trachomatis,

Neisseria gonorrheae,

Candida albicans

MC1220 (Lead

Idenix Pharmaceuticals,

HIV-l, Hepatitis B, Herpes

compound of

Inc.

simplex, Haemophilus

Dihydroxy Alkyl

ducreyi, Neisseria

Benzyl

gonorrheae,

Oxopyrimidine

Trichomonas vaginalis,

series)

Candida albicans,

Bacillus subtilis,

Staphylococcus aureus,

Candida tropicalis,

Streptococcus

MucoCept HIV

Osel, Inc.

Candida albicans, HIV-l

Novaflux proprietary

Pennsylvania State

HIV-l

product

University

Table 2. Microbicides in Clinical Trials (modified from Alliance for Microbicide Development's Microbicide Research and Development Database (MRDD) and [2])

Product

Developer

Infectious agents in vitro and/ or animal model data

Clinical trial phase

Pro2000/5 Gel

Protected lactobacilli in combination with BZK

Savvy (C31G) Tenofovir/PMPA gel TMC120

UC-781

ACIDFORM gel BufferGelTM

Carraguard® Cellulose acetate 1,2-benzenedicarboxylate (cellacetate/CAP)

Cellulose sulfate gel Human monoclonal antibodies C2F5, C2G12, C4E10 Invisible Condom

Lactin-Vaginal (Lactin Vaginal Capsule)

Polystyrene sulfonate gel (PSS gel)

Indevus Pharmaceuticals, Inc.

Biofem, Inc.

Biosyn, Inc. Gilead Sciences, Inc. International Partnership for Microbicides

Biosyn, Inc.

Global Microbicide Project Reprotect, LLC

Population Council New York Blood Center (NY, USA)

Global Microbicide Project Polymun Scientific

Laval University

University of Pittsburgh

Global Microbicide Project/TOPCAD/ CONRAD

HIV-1, Herpes simplex, Phase 1

Chlamydia trachomatis, Neisseria gonorrheae HIV-1, Chlamydia Phase 1

trachomatis, Neisseria gonorrheae, Candida albicans, Streptococcus agalactiae, Escherichia coli, Pseudomonas aeruginosa HIV-1 Phase 3

HIV-1 Phase 2

Neisseria gonorrheae, Phase 1

Haemophilus ducreyi, HIV-1, Herpes simplex, human papillomavirus, Candida albicans HIV-1 Phase 1

(Vaginal Defense Enhancer) Phase 1 HIV-1, Treponema pallidum, Phase 1 Herpes simplex, Chlamydia trachomatis, Haemophilus ducreyi, Neisseria gonorrheae, Trichomonas vaginalis, BV-associated bacteria, Staphylococcus aureus, human papillomavirus HIV-1 Phase 1

HIV-1, Chlamydia Phase 1

trachomatis, Herpes simplex, Haemophilus ducreyi, Neisseria gonorrheae, Trichomonas vaginalis, Candida albicans, Garnerella vaginalis

HIV-1 Phase 1

HIV-1 Phase 1

HIV-l, Herpes simplex, Phase 1/2

human papillomavirus, Chlamydia trachomatis, HIV-1, Neisseria gonorrheae HIV-1, Chlamydia Phase 1

trachomatis, Neisseria gonorrheae, Trichomonas vaginalis, Candida albicans HIV-1 Phase 1

Table 2. Continued

Infectious agents in vitro and/ Clinical Product Developer or animal model data trial phase

Infectious agents in vitro and/ Clinical Product Developer or animal model data trial phase

Table 2. Continued

VivaGel (SPL7013 gel)

Starpharma, Ltd.

HIV-1 Herpes simplex, Chlamydia trachomatis

Phase 1

Dextran/Dextrin sulfate/

Institute of Tropical

HIV-1, Herpes simplex,

Phase 1/2

Emmelle™

Medicine, Imperial College School of Medicine, Medical Research Council, England

Chlamydia trachomatis

Praneem tablet

M/S reproductive Technologies (New Delhi, India)

HIV-1

Phase 1/2

For more information on candidate microbicides and trials, consult the Alliance for Microbicide Development's Microbicide Research and Development Database (MRDD) at www.microbicide.org.

For more information on candidate microbicides and trials, consult the Alliance for Microbicide Development's Microbicide Research and Development Database (MRDD) at www.microbicide.org.

How To Get Rid Of Yeast Infections Once And For All

How To Get Rid Of Yeast Infections Once And For All

No more itching, odor or pain or your money is refunded! Safe and DRUG FREE Natural Yeast Infection Solutions Are you looking for a safe, fast and permanent cure for your chronic yeast infection? Get Rid of that Yeast Infection Right Now and For Good!

Get My Free Ebook


Post a comment